Cargando…
Predictive Biomarkers of Dicycloplatin Resistance or Susceptibility in Prostate Cancer
BACKGROUND: Prostate cancer (PCa) is among the leading causes of cancer mortality. Dicycloplatin is a newer generation platinum-based drug that has less side effects than cisplatin and carboplatin. However, its effects in PCa is mixed due to lack of appropriate stratifying biomarkers. Aiming to sear...
Autores principales: | Liu, Minglu, Zhou, Xiaoyu, Liu, Jun, Lu, Chelong, Zhang, Guoqing, Zhang, Jing, Jiao, Shunchang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353331/ https://www.ncbi.nlm.nih.gov/pubmed/34386035 http://dx.doi.org/10.3389/fgene.2021.669605 |
Ejemplares similares
-
TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients
por: Zhang, Jian, et al.
Publicado: (2022) -
Effect of Dicycloplatin, a Novel Platinum Chemotherapeutical Drug, on Inhibiting Cell Growth and Inducing Cell Apoptosis
por: Li, Guang-quan, et al.
Publicado: (2012) -
Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021) -
Comparison of Gene Expression Between Resistant and Susceptible Families Against VP(AHPND) and Identification of Biomarkers Used for Resistance Evaluation in Litopenaeus vannamei
por: Zhang, Qian, et al.
Publicado: (2021) -
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
por: Liu, Ke-Jun, et al.
Publicado: (2014)